Michaela M Hell, Mirjam G Wild, Stephan Baldus, Tanja Rudolph, Hendrik Treede, Anna Sonia Petronio, Thomas Modine, Martin Andreas, Augustin Coisne, Alison Duncan, Luis Nombela Franco, Fabien Praz, Hendrik Ruge, Lenard Conradi, Andreas Zierer, Amedeo Anselmi, Nicolas Dumonteil, Georg Nickenig, Miguel Piñón, Sebastian Barth, Marianna Adamo, Christophe Dubois, Lucia Torracca, Francesco Maisano, Philipp Lurz, Ralph Stephan von Bardeleben, Jörg Hausleiter
BACKGROUND: Early studies of the Tendyne transcatheter mitral valve replacement (TMVR) showed promising results in a small selective cohort. OBJECTIVES: The authors present 1-year data from the currently largest commercial, real-world cohort originating from the investigator-initiated TENDER (Tendyne European Experience) registry. METHODS: All patients from the TENDER registry eligible for 1-year follow-up were included. The primary safety endpoint was 1-year cardiovascular mortality...
February 15, 2024: JACC. Cardiovascular Interventions